Gene: XDH
Official Full Name: xanthine dehydrogenaseprovided by HGNC
Gene Summary: Xanthine dehydrogenase belongs to the group of molybdenum-containing hydroxylases involved in the oxidative metabolism of purines. The encoded protein has been identified as a moonlighting protein based on its ability to perform mechanistically distinct functions. Xanthine dehydrogenase can be converted to xanthine oxidase by reversible sulfhydryl oxidation or by irreversible proteolytic modification. Defects in xanthine dehydrogenase cause xanthinuria, may contribute to adult respiratory stress syndrome, and may potentiate influenza infection through an oxygen metabolite-dependent mechanism. [provided by RefSeq, Jan 2014]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO00250 | XDH Knockout cell line (HeLa) | Human | XDH | 1:3~1:6 | Negative | Online Inquiry |
KO06298 | XDH Knockout cell line (A549) | Human | XDH | 1:3~1:4 | Negative | Online Inquiry |
XDH Gene Knockout Cell Lines are a specialized tool designed for the study of xanthine dehydrogenase (XDH), an enzyme critical in purine metabolism and associated with various metabolic disorders and pathologies, including gout, ischemia, and some neurodegenerative diseases. These engineered cell lines have been meticulously crafted using CRISPR-Cas9 technology to specifically disrupt the XDH gene, enabling researchers to understand the biological implications of XDH inhibition and its potential therapeutic targets.
The primary function of these knockout cell lines is to serve as a model for assessing the cellular and molecular consequences of XDH deficiency. By eliminating the XDH gene, researchers can investigate alterations in metabolic pathways and identify compensatory mechanisms activated under conditions of enzymatic deficiency. Furthermore, these cell lines facilitate high-throughput screening of potential inhibitors, which can lead to the development of novel therapeutics aimed at modulating XDH activity.
Scientifically, these XDH Gene Knockout Cell Lines are invaluable in both research and clinical applications. In laboratories, they provide a precise in vitro model for drug discovery, allowing for the assessment of pharmacokinetics and pharmacodynamics of compounds targeting XDH. In clinical settings, understanding the functions of XDH opens avenues for developing targeted therapies for patients suffering from related metabolic disorders.
What sets our XDH Gene Knockout Cell Lines apart from alternative models is the assurance of validated genetic modification, high reproducibility, and ease of use across various experimental designs. Unlike other models, our cell lines have been optimized for minimal off-target effects, thus ensuring reliable results.
For researchers, clinicians, and biopharmaceutical companies, the insights gained from using these knockout cell lines can revolutionize treatment approaches and enhance patient care. By harnessing the potential of XDH manipulation, users can pursue innovative solutions to complex health challenges.
Our company prides itself on its commitment to advancing scientific research through high-quality biological tools that are grounded in cutting-edge technology and deep expertise. We offer a range of genetic models, including our XDH Gene Knockout Cell Lines, aimed at empowering the scientific community toward groundbreaking discoveries.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.